{"success":true,"data":{"pressRelease":{"id":"162641","rtpr_id":"nBw1DhgKva-20261007","ticker":"ALVIO","exchange":"Euronext Paris","all_tickers":["ALVIO"],"title":"Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026","author":"Business Wire","published_at":"2026-10-07T06:21:00.129Z","article_body":"Valerio Therapeutics Provides an Update on Its Business and Presents Its\nFinancial Results for the First Half of 2026\n\n\n * Operational launch of InVimmune, a subsidiary dedicated to differentiated\napproaches to in vivo cell therapy, with a first indication announced in\noncology.\n\n\n * Appointment of Gilles Besin as Chief Executive Officer, effective( )July 2026.\n\n\n * Signing of a binding term sheet with Abivax with a view to an exclusive global\ncollaboration.\n\n\n * Achievement of a major strategic milestone with the acquisition of Etherna\nImmunotherapies NV; the transaction is expected to be finalised on 8 October\n2026.\n\n\n * Cash and cash equivalents totaling €656,000 as at 30 June 2026. As of the\ndate of the half-year financier report, the cash position covers 12 months.\n\nRegulatory News:\n\nValerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology\ncompany in the field of next-generation precision therapies (“Valerio”, or\nthe “Company”), provides an update on its operations and presents its\nfinancial results for the half-year ended 30 June 2026.\n\n“The first half of 2026 marked a decisive milestone in the consolidation of\nour strategic refocusing and in the transformation of Valerio Therapeutics.\nThe operational launch of InVimmune, the strengthening of our partnerships,\nthe signing of the definitive agreement for the acquisition of Etherna and the\ngovernance transition demonstrate our ability to implement our roadmap with\ndetermination, consistency and discipline. These complementary advances\nstrengthen our positioning and open up new prospects for therapeutic\ndevelopment. We now have a solid foundation on which to accelerate the\ndevelopment of our targeted RNA delivery platform, deepen scientific and\noperational synergies within the Group, and advance our proprietary programmes\ntowards key milestones that are likely to create sustainable value for our\npatients, partners and shareholders,” said Gilles Besin, Chief Executive\nOfficer of Valerio Therapeutics.\n\nConsolidation of the group’s strategic refocusing\n\nValerio Therapeutics has continued the strategic refocus initiated in 2025,\naimed at positioning the Company as a specialist in the development of\nRNA-based precision therapies, with a focus on targeted delivery beyond the\nliver. This consolidation has resulted in several significant milestones.\n\nThe Company launched InVimmune, its subsidiary dedicated to the development of\ndifferentiated in vivo cell therapy approaches, with a first indication\nannounced in oncology.\n\nAs part of a planned governance transition, Gilles Besin took up his position\nas Chief Executive Officer of the Company on 1 July 2026, succeeding Julien\nMiara, to lead this new phase of development focused on RNA-based medicines\nand targeted delivery.\n\nIn addition, the Company’s partnership strategy has been strengthened\nthrough the conclusion of key partnerships:\n\n- Valerio has entered into a definitive collaboration agreement and an\nexclusive global licence, providing for an upfront payment of 740,000 euros\nand an additional payment of 500,000 US dollars upon the signing of the\ndefinitive collaboration and licence agreement on 29 May 2026. It also\nprovides for conditional future payments of up to US$200 million, to which\nsales royalties may be added,\n\n- Valerio has also entered into a binding term sheet with Abivax SA\n(“Abivax”) setting out the key terms of an exclusive global research and\ndevelopment collaboration(1). This term sheet provides for an initial payment\nof up to 2.4 million euros, supplemented – subject, in particular, to the\nconclusion of the definitive co-ownership and licence agreement and the\nachievement of the corresponding milestones – by milestone payments and\nroyalties.\n\nThe Company also reached a major milestone with the signing, on 24 August\n2026, of a definitive share purchase agreement as part of the acquisition of\n100% of the share capital and voting rights of Etherna Immunotherapies NV; the\nintegration of this company brings together, within a single platform,\nproprietary capabilities in V-Body, active targeting, chemistry and\nbioconjugation, mRNA and lipid nanoparticle technologies, as well as\nmanufacturing capabilities, within a single platform. The general meeting held\non 6 October 2026 approved the capital increase in consideration for\ncontributions in kind and the capital increases by way of set-off against\ncertain claims held by lenders and directors of Etherna. The completion of the\ntransaction is scheduled on 8 October.\n\nIn August 2026, the Company carried out a capital increase of c. €40.25\nmillion, achieved through the issue of 68,220,333 new shares at a subscription\nprice of €0.59 per share, supported by its existing shareholders and new\ninvestors(2).\n\nFinancial results for the first half of 2026\n\n\n * Turnover: The Group recorded consolidated turnover of €3,102,000 for the\nperiod ending 30 June 2026, compared with €126,000 as at 30 June 2025.\n\n\n * Financial result: The financial result as of 30 June 2026 was a loss of €137\n000, compared with a loss of €285 000 as of June 30, 2025.\n\n\n * Consolidated net profit: Consequently, the consolidated net result as of 30\nJune 2026 was a loss of €2 361 000, compared with a loss of €208 000 as of\n30 June 2025.\n\n\n * Cash position: The Group’s balance of cash and cash equivalents as at 30\nJune 2026 stood at €656,000, compared with €1,053,000 as at 31 December\n2025. As of the date of the half-year financial report, based on its current\noperating plan and expenditure forecasts, and taking into account its cash and\ncash equivalents, the Company estimates that it has sufficient resources to\nfinance its operations and capital expenditure for at least 12 months.\n\nShareholders General Meeting of 6 October 2026\n\nThe shareholders general meeting held on 6 October 2026 approved all the\nresolutions recommended by the Board of Directors.\n\nThe results of the votes will be made available on the Company’s website\n(https://valeriotx.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvaleriotx.com%2F&esheet=54617524&newsitemid=20261006747184&lan=en-US&anchor=https%3A%2F%2Fvaleriotx.com%2F&index=1&md5=00e21727797a359dfd7a6b4bfd558d2e)\n).\n\n******\n\nAbout Valerio Therapeutics\n\nValerio Therapeutics (FR0010095596 – ALVIO) is a biotechnology company\nspecialising in the development of technological platforms dedicated to the\ntargeted delivery of innovative treatments. The Company is listed on Euronext\nGrowth Paris.\n\nFor further information: https://valeriotx.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvaleriotx.com%2F&esheet=54617524&newsitemid=20261006747184&lan=en-US&anchor=https%3A%2F%2Fvaleriotx.com%2F&index=2&md5=958c876049534001d6c52d8bd5c2a784)\n.\n\nForward-looking statements\n\nThis press release contains certain forward-looking statements concerning\nValerio Therapeutics and its activities. These forward-looking statements are\nbased on assumptions that Valerio Therapeutics considers reasonable. However,\nthere is no guarantee that these forward-looking statements will prove to be\naccurate, as they are subject to numerous risks, including those set out in\nthe 2025 Annual Financial Report published on 28 April 2026, and the 2026\nhalf-yearly financial report published on 7 October 2026, both available on\nthe Valerio Therapeutics website, as well as to changes in the economic\nenvironment, the financial markets and the markets in which Valerio\nTherapeutics operates. The forward-looking statements contained in this press\nrelease are also subject to risks that are not yet known to Valerio\nTherapeutics or that are not currently considered material by Valerio\nTherapeutics. The materialisation of all or part of these risks could cause\nValerio Therapeutics’ actual results, financial position, performance or\nachievements to differ materially from those set out in these forward-looking\nstatements. This press release and the information it contains do not\nconstitute an offer to sell or subscribe for, or a solicitation of an offer to\nbuy or subscribe for, Valerio Therapeutics shares in any country. The\ndistribution of this press release in certain countries may constitute a\nbreach of local laws and regulations. Any recipient of this press release must\nfamiliarise themselves with and comply with such local restrictions.\n\n(1) Press release – 16 July 2026 \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvaleriotx.com%2Ffr%2Fvalerio-therapeutics-annonce-une-collaboration-de-developpement-avec-abivax-et-met-a-jour-son-pipeline%2F&esheet=54617524&newsitemid=20261006747184&lan=en-US&anchor=16+July+2026&index=3&md5=47dc8c6dd7fb0cab7ec39239305de818)\n\n(2) Press release – 24 August 2026\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvaleriotx.com%2Ffr%2Fvalerio-therapeutics-annonce-la-signature-daccords-definitifs-en-vue-de-lacquisition-detherna-immunotherapies-creant-ainsi-un-leader-mondial-des-medicaments-a-base-d-2%2F&esheet=54617524&newsitemid=20261006747184&lan=en-US&anchor=24+August+2026&index=4&md5=62c80c8bf0e7bd325184ea5549987872)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261006747184/en/\n(https://www.businesswire.com/news/home/20261006747184/en/)\n\nValerio Therapeutics \n\nInvestor Relations: ir@valeriotx.com (mailto:ir@valeriotx.com) | +33 (0) 1 45\n58 95 10\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1DhgKva-20261007","title":"Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026","author":"Business Wire","ticker":"ALVIO","created":"2026-10-07T06:21:00.129Z","tickers":["ALVIO"],"exchange":"Euronext Paris","article_body":"Valerio Therapeutics Provides an Update on Its Business and Presents Its\nFinancial Results for the First Half of 2026\n\n\n * Operational launch of InVimmune, a subsidiary dedicated to differentiated\napproaches to in vivo cell therapy, with a first indication announced in\noncology.\n\n\n * Appointment of Gilles Besin as Chief Executive Officer, effective( )July 2026.\n\n\n * Signing of a binding term sheet with Abivax with a view to an exclusive global\ncollaboration.\n\n\n * Achievement of a major strategic milestone with the acquisition of Etherna\nImmunotherapies NV; the transaction is expected to be finalised on 8 October\n2026.\n\n\n * Cash and cash equivalents totaling €656,000 as at 30 June 2026. As of the\ndate of the half-year financier report, the cash position covers 12 months.\n\nRegulatory News:\n\nValerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology\ncompany in the field of next-generation precision therapies (“Valerio”, or\nthe “Company”), provides an update on its operations and presents its\nfinancial results for the half-year ended 30 June 2026.\n\n“The first half of 2026 marked a decisive milestone in the consolidation of\nour strategic refocusing and in the transformation of Valerio Therapeutics.\nThe operational launch of InVimmune, the strengthening of our partnerships,\nthe signing of the definitive agreement for the acquisition of Etherna and the\ngovernance transition demonstrate our ability to implement our roadmap with\ndetermination, consistency and discipline. These complementary advances\nstrengthen our positioning and open up new prospects for therapeutic\ndevelopment. We now have a solid foundation on which to accelerate the\ndevelopment of our targeted RNA delivery platform, deepen scientific and\noperational synergies within the Group, and advance our proprietary programmes\ntowards key milestones that are likely to create sustainable value for our\npatients, partners and shareholders,” said Gilles Besin, Chief Executive\nOfficer of Valerio Therapeutics.\n\nConsolidation of the group’s strategic refocusing\n\nValerio Therapeutics has continued the strategic refocus initiated in 2025,\naimed at positioning the Company as a specialist in the development of\nRNA-based precision therapies, with a focus on targeted delivery beyond the\nliver. This consolidation has resulted in several significant milestones.\n\nThe Company launched InVimmune, its subsidiary dedicated to the development of\ndifferentiated in vivo cell therapy approaches, with a first indication\nannounced in oncology.\n\nAs part of a planned governance transition, Gilles Besin took up his position\nas Chief Executive Officer of the Company on 1 July 2026, succeeding Julien\nMiara, to lead this new phase of development focused on RNA-based medicines\nand targeted delivery.\n\nIn addition, the Company’s partnership strategy has been strengthened\nthrough the conclusion of key partnerships:\n\n- Valerio has entered into a definitive collaboration agreement and an\nexclusive global licence, providing for an upfront payment of 740,000 euros\nand an additional payment of 500,000 US dollars upon the signing of the\ndefinitive collaboration and licence agreement on 29 May 2026. It also\nprovides for conditional future payments of up to US$200 million, to which\nsales royalties may be added,\n\n- Valerio has also entered into a binding term sheet with Abivax SA\n(“Abivax”) setting out the key terms of an exclusive global research and\ndevelopment collaboration(1). This term sheet provides for an initial payment\nof up to 2.4 million euros, supplemented – subject, in particular, to the\nconclusion of the definitive co-ownership and licence agreement and the\nachievement of the corresponding milestones – by milestone payments and\nroyalties.\n\nThe Company also reached a major milestone with the signing, on 24 August\n2026, of a definitive share purchase agreement as part of the acquisition of\n100% of the share capital and voting rights of Etherna Immunotherapies NV; the\nintegration of this company brings together, within a single platform,\nproprietary capabilities in V-Body, active targeting, chemistry and\nbioconjugation, mRNA and lipid nanoparticle technologies, as well as\nmanufacturing capabilities, within a single platform. The general meeting held\non 6 October 2026 approved the capital increase in consideration for\ncontributions in kind and the capital increases by way of set-off against\ncertain claims held by lenders and directors of Etherna. The completion of the\ntransaction is scheduled on 8 October.\n\nIn August 2026, the Company carried out a capital increase of c. €40.25\nmillion, achieved through the issue of 68,220,333 new shares at a subscription\nprice of €0.59 per share, supported by its existing shareholders and new\ninvestors(2).\n\nFinancial results for the first half of 2026\n\n\n * Turnover: The Group recorded consolidated turnover of €3,102,000 for the\nperiod ending 30 June 2026, compared with €126,000 as at 30 June 2025.\n\n\n * Financial result: The financial result as of 30 June 2026 was a loss of €137\n000, compared with a loss of €285 000 as of June 30, 2025.\n\n\n * Consolidated net profit: Consequently, the consolidated net result as of 30\nJune 2026 was a loss of €2 361 000, compared with a loss of €208 000 as of\n30 June 2025.\n\n\n * Cash position: The Group’s balance of cash and cash equivalents as at 30\nJune 2026 stood at €656,000, compared with €1,053,000 as at 31 December\n2025. As of the date of the half-year financial report, based on its current\noperating plan and expenditure forecasts, and taking into account its cash and\ncash equivalents, the Company estimates that it has sufficient resources to\nfinance its operations and capital expenditure for at least 12 months.\n\nShareholders General Meeting of 6 October 2026\n\nThe shareholders general meeting held on 6 October 2026 approved all the\nresolutions recommended by the Board of Directors.\n\nThe results of the votes will be made available on the Company’s website\n(https://valeriotx.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvaleriotx.com%2F&esheet=54617524&newsitemid=20261006747184&lan=en-US&anchor=https%3A%2F%2Fvaleriotx.com%2F&index=1&md5=00e21727797a359dfd7a6b4bfd558d2e)\n).\n\n******\n\nAbout Valerio Therapeutics\n\nValerio Therapeutics (FR0010095596 – ALVIO) is a biotechnology company\nspecialising in the development of technological platforms dedicated to the\ntargeted delivery of innovative treatments. The Company is listed on Euronext\nGrowth Paris.\n\nFor further information: https://valeriotx.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvaleriotx.com%2F&esheet=54617524&newsitemid=20261006747184&lan=en-US&anchor=https%3A%2F%2Fvaleriotx.com%2F&index=2&md5=958c876049534001d6c52d8bd5c2a784)\n.\n\nForward-looking statements\n\nThis press release contains certain forward-looking statements concerning\nValerio Therapeutics and its activities. These forward-looking statements are\nbased on assumptions that Valerio Therapeutics considers reasonable. However,\nthere is no guarantee that these forward-looking statements will prove to be\naccurate, as they are subject to numerous risks, including those set out in\nthe 2025 Annual Financial Report published on 28 April 2026, and the 2026\nhalf-yearly financial report published on 7 October 2026, both available on\nthe Valerio Therapeutics website, as well as to changes in the economic\nenvironment, the financial markets and the markets in which Valerio\nTherapeutics operates. The forward-looking statements contained in this press\nrelease are also subject to risks that are not yet known to Valerio\nTherapeutics or that are not currently considered material by Valerio\nTherapeutics. The materialisation of all or part of these risks could cause\nValerio Therapeutics’ actual results, financial position, performance or\nachievements to differ materially from those set out in these forward-looking\nstatements. This press release and the information it contains do not\nconstitute an offer to sell or subscribe for, or a solicitation of an offer to\nbuy or subscribe for, Valerio Therapeutics shares in any country. The\ndistribution of this press release in certain countries may constitute a\nbreach of local laws and regulations. Any recipient of this press release must\nfamiliarise themselves with and comply with such local restrictions.\n\n(1) Press release – 16 July 2026 \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvaleriotx.com%2Ffr%2Fvalerio-therapeutics-annonce-une-collaboration-de-developpement-avec-abivax-et-met-a-jour-son-pipeline%2F&esheet=54617524&newsitemid=20261006747184&lan=en-US&anchor=16+July+2026&index=3&md5=47dc8c6dd7fb0cab7ec39239305de818)\n\n(2) Press release – 24 August 2026\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvaleriotx.com%2Ffr%2Fvalerio-therapeutics-annonce-la-signature-daccords-definitifs-en-vue-de-lacquisition-detherna-immunotherapies-creant-ainsi-un-leader-mondial-des-medicaments-a-base-d-2%2F&esheet=54617524&newsitemid=20261006747184&lan=en-US&anchor=24+August+2026&index=4&md5=62c80c8bf0e7bd325184ea5549987872)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261006747184/en/\n(https://www.businesswire.com/news/home/20261006747184/en/)\n\nValerio Therapeutics \n\nInvestor Relations: ir@valeriotx.com (mailto:ir@valeriotx.com) | +33 (0) 1 45\n58 95 10\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-07T06:21:00.174657053Z","server_sent_at_ms":1791354060174},"received_at":"2026-10-07T06:21:00.225Z","source_url":"https://www.businesswire.com/news/home/20261006747184/en/"},"analysis":{"id":"151121","press_release_id":"162641","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Cash of only €656,000 at 30 June 2026 with a widening net loss (€2.361M vs €208,000 prior year); 12-month runway depends on post-period financing","Heavy dilution: 68.2 million new shares issued at €0.59 in August 2026, plus capital increases in kind for the Etherna deal","Acquisition of Etherna closing 8 October 2026 not yet completed at report date"],"eventType":"earnings","narrative":"Valerio Therapeutics reported H1 2026 turnover of €3.102 million (vs €126,000 a year earlier) alongside a widening net loss of €2.361 million and cash of just €656,000 at 30 June 2026.\n\nThe company says its current cash covers at least 12 months of operations, though that assessment predates closing of the Etherna acquisition, scheduled for 8 October 2026.\n\nKey strategic moves include the acquisition of 100% of Etherna Immunotherapies, launch of the InVimmune subsidiary in oncology, a binding term sheet with Abivax, and a collaboration carrying up to US$200 million in conditional payments.\n\nGilles Besin became CEO on 1 July 2026, succeeding Julien Miara; the August capital increase issued 68,220,333 new shares at €0.59, raising c. €40.25 million.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Transformational Etherna close-upcoming but watch the thin €656k cash position and heavy dilution."},"keyFigures":{"revenue":3102000,"customDimensions":{"new_shares_issued":68220333,"cash_runway_months":12,"prior_year_revenue":126000,"prior_year_net_loss":208000,"capital_increase_eur":40250000,"cash_and_equivalents":656000,"financial_result_loss":137000,"subscription_price_eur":0.59,"collaboration_upfront_eur":740000,"abivax_term_sheet_initial_payment_eur":2400000,"collaboration_milestone_payments_usd_up_to":200000000}},"quotedText":"The Group's balance of cash and cash equivalents as at 30 June 2026 stood at €656,000, compared with €1,053,000 as at 31 December 2025.","namedEntities":{"people":[{"name":"Gilles Besin","role":"CEO (effective 1 July 2026)"},{"name":"Julien Miara","role":"former CEO (succeeded)"}],"products":["V-Body","targeted RNA delivery platform"],"companies":[{"name":"Valerio Therapeutics","ticker":"ALVIO","relationship":"filer"},{"name":"Abivax SA","relationship":"collaboration partner"},{"name":"Etherna Immunotherapies NV","relationship":"acquisition target"},{"name":"InVimmune","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"€656,000","context":"cash and cash equivalents as at 30 June 2026"},{"amount":"c. €40.25 million","context":"August 2026 capital increase"},{"amount":"€3,102,000","context":"H1 2026 consolidated turnover"},{"amount":"€2 361 000","context":"H1 2026 consolidated net loss"},{"amount":"US$200 million","context":"maximum conditional future payments under collaboration agreement"},{"amount":"740,000 euros","context":"upfront payment under definitive collaboration agreement"},{"amount":"2.4 million euros","context":"initial payment under Abivax binding term sheet"},{"amount":"€0.59","context":"subscription price per new share"}]},"materialImpact":{"score":3,"reasoning":"Transformational half-year report: Etherna acquisition closing 8 October, ~€40.25M capital increase (heavy dilution via 68.2M new shares), new CEO, and multiple partnerships. But the cash position of only €656,000 at 30 June with a widening net loss offsets the positives."},"tickerRelevance":{"others":[],"primary":"ALVIO"},"globalImportance":20,"audienceRelevance":10,"eventTypeSecondary":["m_and_a","executive_change","partnership"],"importanceComponents":{"tickerTier":"micro-cap Euronext Growth","eventGravity":"half-year results plus pending M&A close and dilution","issuerAuthored":true}},"event_type":"earnings","event_type_secondary":["m_and_a","executive_change","partnership"],"sentiment":"mixed","material_impact_score":3,"narrative":"Valerio Therapeutics reported H1 2026 turnover of €3.102 million (vs €126,000 a year earlier) alongside a widening net loss of €2.361 million and cash of just €656,000 at 30 June 2026.\n\nThe company says its current cash covers at least 12 months of operations, though that assessment predates closing of the Etherna acquisition, scheduled for 8 October 2026.\n\nKey strategic moves include the acquisition of 100% of Etherna Immunotherapies, launch of the InVimmune subsidiary in oncology, a binding term sheet with Abivax, and a collaboration carrying up to US$200 million in conditional payments.\n\nGilles Besin became CEO on 1 July 2026, succeeding Julien Miara; the August capital increase issued 68,220,333 new shares at €0.59, raising c. €40.25 million.","key_figures":{"revenue":3102000,"customDimensions":{"new_shares_issued":68220333,"cash_runway_months":12,"prior_year_revenue":126000,"prior_year_net_loss":208000,"capital_increase_eur":40250000,"cash_and_equivalents":656000,"financial_result_loss":137000,"subscription_price_eur":0.59,"collaboration_upfront_eur":740000,"abivax_term_sheet_initial_payment_eur":2400000,"collaboration_milestone_payments_usd_up_to":200000000}},"named_entities":{"people":[{"name":"Gilles Besin","role":"CEO (effective 1 July 2026)"},{"name":"Julien Miara","role":"former CEO (succeeded)"}],"products":["V-Body","targeted RNA delivery platform"],"companies":[{"name":"Valerio Therapeutics","ticker":"ALVIO","relationship":"filer"},{"name":"Abivax SA","relationship":"collaboration partner"},{"name":"Etherna Immunotherapies NV","relationship":"acquisition target"},{"name":"InVimmune","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"€656,000","context":"cash and cash equivalents as at 30 June 2026"},{"amount":"c. €40.25 million","context":"August 2026 capital increase"},{"amount":"€3,102,000","context":"H1 2026 consolidated turnover"},{"amount":"€2 361 000","context":"H1 2026 consolidated net loss"},{"amount":"US$200 million","context":"maximum conditional future payments under collaboration agreement"},{"amount":"740,000 euros","context":"upfront payment under definitive collaboration agreement"},{"amount":"2.4 million euros","context":"initial payment under Abivax binding term sheet"},{"amount":"€0.59","context":"subscription price per new share"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T06:21:09.515Z","global_importance":20,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap Euronext Growth","eventGravity":"half-year results plus pending M&A close and dilution","issuerAuthored":true}},"durationMs":9280,"modelName":"glm-5.3-flashx"}}